Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?

• Main Authors: Rosaria Vincenza Giglio BD, PhD (Author), Emir M. Muzurović MD, PhD (Author), Angelo Maria Patti MD, PhD (Author), Peter P. Toth MD, PhD (Author), Manyoo A. Agarwal MD (Author), Wael Almahmeed MD (Author), Aleksandra Klisic MD, PhD (Author), Marcello Ciaccio MD, PhD (Author), Manfredi Rizzo MD, PhD (Author)
• Format: Book
• Published: SAGE Publishing, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are low-density lipoprotein cholesterol (LDL-C)-lowering drugs that play a critical role in lipoprotein clearance and metabolism. PCSK9i are used in patients with familial hypercholesterolemia and for the secondary prevent...